Prevention of catheter-related infections using a closed hub system in patients with pulmonary arterial hypertension

Circ J. 2007 Apr;71(4):559-64. doi: 10.1253/circj.71.559.


Background: Most of the patients with pulmonary arterial hypertension (PAH) receiving intravenous epoprostenol have experienced catheter-related infections during long-term treatment. Catheter hub was reported to be the most important source of catheter-related infections. To prevent the catheter-related infections, we have introduced a closed hub system and compared the incidence of catheter-related infections with that in patients using a non-closed hub system.

Methods and results: We evaluated the results obtained on 24 occasions in 20 patients with PAH between June 1999 and December 2005. On 11 occasions, a non-closed hub system was used and on 13 cases a closed hub system. We classified the catheter-related infection into a catheter-related bloodstream infection (CRBSI) group or a tunnel infection group based on the pathway of bacteria. The CRBSI rate was 0.89 per 1,000 catheter days in the non-closed hub system group vs 0.10 per 1,000 catheter days in the closed hub system group. Kaplan-Meier analysis showed that the risk of CRBSI significantly decreased in the closed hub system group. None of the patients died as a direct consequence of catheter-related infection during the study period.

Conclusions: We successfully prevented CRBSI by using a closed hub system.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Antihypertensive Agents / administration & dosage*
  • Bacterial Infections / prevention & control*
  • Catheterization, Central Venous / adverse effects
  • Catheterization, Central Venous / instrumentation
  • Catheterization, Central Venous / methods*
  • Catheters, Indwelling / adverse effects
  • Catheters, Indwelling / microbiology*
  • Epoprostenol / administration & dosage*
  • Equipment Contamination
  • Female
  • Humans
  • Hypertension, Pulmonary / drug therapy*
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Pulmonary Artery / physiopathology


  • Antihypertensive Agents
  • Epoprostenol